Sign In
Buy ELVN
$59.42
-1.04 (-1.72%)
At Close: Aug 10, 2026
U.S. IPO Week Ahead: No IPOs, But Plenty Of Potential Launches In The Short Holiday Week
01:14pm, Sunday, 06'th Sep 2020
Just one SPAC is scheduled for the week ahead. More SPACs may join the IPO calendar, and another wave of new filings will likely hit after Labor Day as well.
Wall Street Breakfast: The Week Ahead
04:42am, Sunday, 06'th Sep 2020
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
Stocks To Watch: Tech Reboots And Eyes On Lululemon, Peloton & GameStop
08:21am, Saturday, 05'th Sep 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday
TG Therapeutics Umbralisib Development, And Other News: The Good, Bad And Ugly Of Biopharma
12:57pm, Friday, 14'th Aug 2020
TG Therapeutics reports development for Umbralisib. Mesoblast gets FDA nod for Ryoncil.
The Daily Biotech Pulse: Adcom Rules In Favor Of Mesoblast, CureVac IPO, Novavax Clinches UK COVID-19 Vaccine Deal
12:26pm, Friday, 14'th Aug 2020
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 13) * Aerpio Pharmaceuticals Inc (NASDAQ: ARPO) * Fulgent Genetics Inc (NASDAQ: FLGT) * GENMAB A/S/S ADR (NASDAQ: GMAB) * Halozyme Ther
IMARA Inc.'s (IMRA) CEO Rahul Ballal on Q2 2020 Results - Earnings Call Transcript
12:14pm, Friday, 14'th Aug 2020
IMARA Inc. (NASDAQ:IMRA) Q2 2020 Results Earnings Conference Call August 14, 2020, 08:30 AM ET Company Participants Rahul Ballal - Chief Executive Officer Michael Gray - Chief Financial and Chief Oper
Imara Reports Second Quarter 2020 Financial Results and Business Highlights
11:00am, Friday, 14'th Aug 2020
Initiated Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia; First patient dosed in Ardent Phase 2b sickle cell clinical trialReported Phase 2a interim safety and efficac
Imara Announces First Patient Dosed in Ardent Phase 2b Clinical Trial of IMR-687 in Sickle Cell Disease
08:01pm, Thursday, 13'th Aug 2020
Highly selective, potent, small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell diseaseBOSTON, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Imara I
Global Hemoglobinopathy Treatment Drugs Market to Surpass US$ 6.4 Billion by 2027, Says Coherent Market Insights
12:00am, Tuesday, 11'th Aug 2020
The global hemoglobinopathy treatment drugs market is projected to exhibit a CAGR of 8.4% during the forecast period (2020-2027).
Imara to Webcast Conference Call of Second Quarter 2020 Financial Results
11:00am, Friday, 07'th Aug 2020
BOSTON, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients sufferi
Imricor Announces First Sales Collaboration With Philips
12:00am, Tuesday, 04'th Aug 2020
IMRICOR ANNOUNCES FIRST SALES COLLABORATION WITH PHILIPS.
Imricor gets distribution boost in Europe with new Philips deal - Stockhead
01:50am, Friday, 31'st Jul 2020
Medical Tech company Imricor (ASX:IMR) continued its rally from March lows with a new distribution agreement this morning. Amid a flurry of 4C filings for the June quarter, Imricor’s announcement ma
Imara Announces IMR-687 Granted Fast Track Designation and Rare Pediatric Disease Designation for Treatment of Beta-Thalassemia
11:00am, Thursday, 30'th Jul 2020
BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- IMARA Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients sufferi
Imara Added to Membership of U.S. Small-Cap Russell 2000® Index
08:01pm, Monday, 29'th Jun 2020
Imara Inc. (IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemogl
Imara Announces Recipients of Real Impact Grants Program to Support People Affected by Rare Genetic Blood Disorders
11:00am, Thursday, 25'th Jun 2020
BOSTON, June 25, 2020 -- IMARA Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients.
